7 Hills Pharma is an immunotherapy company developing novel small molecules to improve the effectiveness of immune checkpoint inhibitors for cancer and vaccines for infectious diseases. Our lead compound, 7HP349, is a first-in-concept integrin activator that stabilizes cell-cell interactions required for antigen presentation. 7HP349 improves the effectiveness of immune checkpoint inhibitors for cancer, as well as vaccines for influenza, and COVID-19. 7HP349 is the only systemically safe adjuvant that can activate both cellular and humoral immunity.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
7HP349, small molecule, first-in-concept integrin activator
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):